31 – 40 of 52
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Incidence and Associated Risk Factors of Venous Thromboembolism After Open and Laparoscopic Nephrectomy in Patients Administered Short-period Thromboprophylaxis : A Danish Nationwide Population-based Cohort Study
- Contribution to journal › Article
- 2019
-
Mark
Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma : RECUR Database Analysis
- Contribution to journal › Article
-
Mark
Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C. : results from a European multicenter database (R.E.C.U.R.)
- Contribution to journal › Article
-
Mark
European Association of Urology Guidelines on Renal Cell Carcinoma : The 2019 Update
- Contribution to journal › Article
-
Mark
Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival : Results from a European Multicentre Database (RECUR)
- Contribution to journal › Letter
-
Mark
Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
- Contribution to journal › Article
- 2018
-
Mark
Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma
- Contribution to journal › Debate/Note/Editorial
-
Mark
Metastases from Renal Cell Carcinoma. Recurrence Patterns, Detection and Management.
- Thesis › Doctoral thesis (compilation)
-
Mark
Updated European Association of Urology Guidelines : Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer
- Contribution to journal › Article
-
Mark
A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition : The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations
- Contribution to journal › Letter